Fig. 2.

Prevalence of pregnancy and infant outcomes in women exposed to IFN-beta: all cases, in HCP-confirmed cases of pregnancy with confirmed diagnosis of MS, and the general population. Prevalence data are shown with 95% confidence interval for each population from the European IFN-beta Pregnancy Registry. *HCP-confirmed spontaneously reported pregnancy cases with confirmed diagnosis of MS. ^†Values denote the maximum estimate from the general population as obtained from available literature. ^aWang et al. [23]; ^bBuss et al. [18]; ^cCongenital Malformations Registry [21]; ^dQueisser-Luft et al. [22]. HCP healthcare professional, MS multiple sclerosis, TOPFA termination of pregnancy for foetal anomaly